| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Orotic acid potassium acts as a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. As a vitamin B13 derivative, it participates in carbohydrate metabolism and is necessary for the growth and life activities of organisms. The compound is used as a nutritional supplement and as an intermediate for drugs including angiotensin inhibitors. It has liver function-improving effects and promotes the repair of liver cells. |
|---|---|
| ln Vitro |
In vitro studies have evaluated orotic acid potassium for its effects on cell growth and metabolism. As a pyrimidine precursor, it is involved in nucleic acid synthesis and may promote cell proliferation. The compound stimulates the growth of animals, plants, and microorganisms. In cell culture, it is typically dissolved in aqueous buffers and added to media to support pyrimidine biosynthesis.
|
| ln Vivo |
In vivo studies have shown that orotic acid potassium stimulates the growth of animals and participates in carbohydrate metabolism. It has been used as a nutritional supplement and has liver function-improving effects, promoting the repair of liver cells. The compound may be administered orally or via other routes depending on the study design. Dosing regimens vary based on the specific research objectives.
|
| Enzyme Assay |
For non-cellular assays, orotic acid potassium is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated in biochemical assays studying pyrimidine metabolism. Typical protocols involve dissolving the compound in aqueous buffers and analyzing by chromatographic methods. Purity is typically ≥98%. The compound is stable under recommended storage conditions.
|
| Cell Assay |
For in vitro cell-based studies, orotic acid potassium is dissolved in aqueous buffers or cell culture medium and added to cultures at appropriate concentrations. Cells are cultured under standard conditions and treated with the compound to assess effects on proliferation, nucleic acid synthesis, or metabolic activity. The compound may be used as a nutritional supplement in cell culture media. Appropriate controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, orotic acid potassium can be administered via oral gavage or other routes depending on the study design. The compound is used as a nutritional supplement and for studying pyrimidine metabolism in animal models. Dosing solutions should be freshly prepared using appropriate vehicles. Standard animal welfare guidelines should be followed for all in vivo studies.
|
| ADME/Pharmacokinetics |
Orotic acid potassium has a molecular weight of 194.19 and molecular formula C5H3KN2O4. It is a white crystalline or crystalline powder that is very slightly soluble in alcohol and organic solvents and insoluble in ether, odorless, and tasteless. The compound is stable under recommended storage conditions. Storage: keep in a cool, dry place protected from light and moisture. Purity: typically ≥98%.
|
| Toxicity/Toxicokinetics |
Orotic acid potassium is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. As a vitamin B13 derivative, it is generally considered to have low toxicity at appropriate concentrations. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have been established for regulatory purposes.
|
| Additional Infomation |
An intermediate product in pyrimidine synthesis, it plays a role in the chemical conversion between dihydrofolate and tetrahydrofolate.
Orotic acid potassium (CAS 24598-73-0) is also known as 6-carboxyuracil potassium, Vitamin B13 potassium, and orotic acid monopotassium. It is used as a nutritional supplement and as an intermediate for drugs including angiotensin inhibitors. It has liver function-improving effects and promotes the repair of liver cells. The compound is a precursor of pyrimidine bases and is involved in DNA and RNA synthesis. No clinical trials or therapeutic approvals exist for the purified compound as a drug. |
| Molecular Formula |
C5H3KN2O4
|
|---|---|
| Molecular Weight |
194.19
|
| Exact Mass |
193.972
|
| CAS # |
24598-73-0
|
| Related CAS # |
Orotic acid;65-86-1;Orotic acid zinc;68399-76-8
|
| PubChem CID |
23665705
|
| Appearance |
White to off-white solid powder
|
| Density |
2.3534
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
273
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(NC(=O)NC1=O)C(=O)[O-].[K+]
|
| InChi Key |
DHBUISJCVRMTAZ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C5H4N2O4.K/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1
|
| Chemical Name |
potassium;2,4-dioxo-1H-pyrimidine-6-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1496 mL | 25.7480 mL | 51.4960 mL | |
| 5 mM | 1.0299 mL | 5.1496 mL | 10.2992 mL | |
| 10 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
